{"name":"Citius Pharmaceuticals, Inc.","slug":"citius-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Citius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing critical care drug products. The company's pipeline includes several drugs in phase 2 trials, targeting areas such as infectious diseases and oncology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":9156474,"netIncome":-32542912,"cash":4252290,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Hydrocortisone acetate and lidocaine hydrochloride","genericName":"Hydrocortisone acetate and lidocaine hydrochloride","slug":"hydrocortisone-acetate-and-lidocaine-hydrochloride","indication":"Hemorrhoids (internal and external)","status":"marketed"}]}],"pipeline":[{"name":"Hydrocortisone acetate and lidocaine hydrochloride","genericName":"Hydrocortisone acetate and lidocaine hydrochloride","slug":"hydrocortisone-acetate-and-lidocaine-hydrochloride","phase":"marketed","mechanism":"Hydrocortisone acetate reduces inflammation and itching while lidocaine hydrochloride provides local anesthetic relief through topical application.","indications":["Hemorrhoids (internal and external)","Anal fissures","Pruritus ani"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOQVdsamh3Y0w1cGtSZ0JnaGFHbDZlMjZ3T0poOTAwYXZVQmpZYURSOUo2dVB0d2J4ZDdmeklHYkZuM25YcTN5TzF1SHBud2xqcGFwcWRNWk9EUUJRWm80dXdhNGtxZTJqTFdPUVVpa2VuMk1hclBoTk1UNzZXNTVZTHJoc1loTkFhYUpuX2ozbWlnMDFOVzBaNk5IVkk3U3NXTTJTMllvbnJ6RzFtVFhlYXVIbVd1UQ?oc=5","date":"2026-04-06","type":"regulatory","source":"Stock Titan","summary":"Shareholders keep Citius (NASDAQ: CTXR) board and approve Wolf as auditor - Stock Titan","headline":"Shareholders keep Citius (NASDAQ: CTXR) board and approve Wolf as auditor","sentiment":"positive"},{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNdmJiV01ocDVqSGNQb2Q2STlMV19EMmdSRHg0ckNqRVg0eFlPd3BOSHBnSTdpM3pmYzVibFRyQnpTQXRvT3l5NzdWYmNwVmkzTEZKbG8zNDFLTk1vSDFiZXFFWUNyUjFhMmtzWWk5TXo0anZocl9OMWdIZDNwWjZwZTVKMHIteUZldGZUWDlYcUZmYXpQSE9UWG5OdGRxTkFjaG1kZVl5aV9jVmljaGJLT21Ua05MSWwybWF3cTUzek13OXBYM09IUjlpMllXT3Ztd0oxY1VYWHVjVDB3YThaV3dGdGc3c0F5MHc?oc=5","date":"2026-03-31","type":"pipeline","source":"Finviz","summary":"Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development - Finviz","headline":"Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Developm","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPMVNSWk9QT0RGRE5kbmptRWJOZDdEazFEWDVYTTNJazFZRlRrUVJaamxZX01QWTRtTGpvU3NsUE1ldThiVll0U1hub05QQ1hDTUt2U2NIQ1dUd20zUlBDazkwcEJfSEhnSFZyU214em03MVhSWFhVMTJMbElsZktUVXEydU5yUzA?oc=5","date":"2026-03-06","type":"earnings","source":"Yahoo Finance","summary":"Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Yahoo Finance","headline":"Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPUUVmMGtteHNOdXpZVFB4TVRmYzdTSERwZWNhZk4tek1LSEhsLVN3TXh4QTRydXdfbEt2WkN4OWV3QlZXUUM2OVQtNjBpMlR5VHJwVXU3MndPRGpBZ3ZWeUE4ZllleVA2ZXVXQjQ4d1o4TVMzWXV2MkdBYmZydFFIcFVZSkVKbUtKMUdmQ3lFVmJpY0RrSndLcmxXekg4MmpRY0hYZUYzX2JXTWdXOHRTRmw1dHlxT184RTZWaDNlSER3cGNnZVctaERld2RsakVOcWhETmhoU2NXOGtpek10TzU5a0c?oc=5","date":"2026-02-24","type":"pipeline","source":"PR Newswire","summary":"Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program - PR Newswire","headline":"Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNMHBkTllWTHhJZkVVNm5VcmpraWVtSnRid0RHM1FqelBVSzJ3SGdDdVpMV0w0NmxYTE5jQ3VjU2NwY3BuMjhiSFI5RGJqbTZWMTVNU0ZOVkpNdURZQy1qYWJsdWtPd1YtaGQ4QXF3cTdKSnNlUlkxd3U1bDBkblZad1hBd2JidGFyN3pyTWFXU2xlaUJ5VnQ2OERXZW5XdGRqX2E3SXozWjVVR2ZNRTY2c2xWMjJhMUtBSEVZMU1GaGdrV0hjM0dEcVB6REVCMnByaDNnRWU1V1VIcmUzSGU1WHc5M2s5d0cxSGc?oc=5","date":"2026-02-13","type":"earnings","source":"PR Newswire","summary":"Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire","headline":"Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxONDgxU3ZwZTE0VkQtSEQxdFhPTERjZGVhcldVVzl1ZG1yVWhWRUNQT3J5S3NFUmc5SWhlcmtBdkxyeEVla3diaFI0bl9Lcm5QTHhLYThwb0FoRlFCRllxOHdyYi0wZ1o2LUlLaXhBMVZ3ZWczUkRJeFUwcEk0T3FYOG5laWZtMEp3MlozOXprV2t6YzE1Um82cGszNEtlRDFKd0djdmFZQ1ZIZzMzbjlvMXFvWjFHRkw5RFFYRjd2dDV3ZGUyMGxTcFlnbl80QTFHWUFJVFVXSW5mRHVjOUNDaA?oc=5","date":"2026-02-13","type":"earnings","source":"PR Newswire","summary":"Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire","headline":"Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNSEFyMnp6dmZvU2VTQ3N6SWRBM0Q5VDBlMUp6dWhrOUJzNVJfMzNMZFZ5QVZOU3Z1TnFNRlhEcXZ5bUdMZVNrd3lQMjc5eS1rZ2dFTjAwVUVEVU1EbTI1dmMxcVZvdjlCUFdUazFDZWNUUDdTTVVrM1pGTlVDcEFSelZ0TTlERnZld2tvelBtb1NHbFdMbjh2TWhTU0ZqRU04MFc4WW1pckFZcXZXVlhrTlBkclZXMW4xSVRoM2cza3ppYnB4eTJjQXBFWVN5eWlETTd4VFhGeGE4MTdoTHJfM1Q4WVhZT1lEMmNyTGFnUHVjNEF1emQ1M0l0NWVKeWsyT1RYSlBsVQ?oc=5","date":"2026-02-11","type":"pipeline","source":"PR Newswire","summary":"Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire","headline":"Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Unipha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPZFdyamNvNXBRMk1paS1RT1RBNzJ4amZrSHM0OF9ZYXlycV9GZ201REdBQmRQWFEyVERjVmIzUFd5XzlrWVMyYU1TVllvajFkdGtPRzdXM2VWLTRTWGZoSVVlSFlRQTdqWFFucTZTWksxUjZNODdMRjdua3VQcEdSaVBicGdUVnpHbnlXamZER1VVckRWUTZvV0J0cDNkeXdkU3hfVW5WcnhLSUIzM3RNTVNxWFhWVVpzUUlnQ2xFWVZ6bGpfZEVvNFJ6TlUzcXFWQzBaeFZVQTV5VGFUOThBeU1EMUtScjVEMHc?oc=5","date":"2025-12-23","type":"earnings","source":"PR Newswire","summary":"Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - PR Newswire","headline":"Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2013-09-30","revenueHistory":[{"value":0,"period":"2013-09-30"},{"value":0,"period":"2012-09-30"},{"value":0,"period":"2011-09-30"},{"value":0,"period":"2010-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":9156474,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-32542912,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":4252290,"cashHistory":[],"totalAssets":130938025,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}